8 news items
KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema
KALV
18 Jun 24
," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect
KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024
KALV
6 Jun 24
," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future
KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024
KALV
3 Jun 24
goals of treatment in HAE are to achieve total control of the disease and to normalize patients' lives. Despite the availability of numerous
KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema
KALV
31 May 24
," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy
KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024
KALV
24 May 24
of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek
wzvz9vu0
KALV
21 May 24
," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect
zzdhl wlrm7
KALV
1 May 24
Resources focused on sebetralstat for on-demand HAE with goal
73g6ejpv57nkdqzsgmyhzufh2o7sh1mx4x tcw8lwqccg
KALV
3 Apr 24
," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy
- Prev
- 1
- Next